Search

Displaying results 3981 - 3990 of 7284 in total
  1. Drug

    Aminophenazone

    go.drugbank.com/drugs/DB01424
    ApprovedWithdrawn

    Aminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis. … The FDA suspended the use of aminophenazone due to its association with agranulocytosis, a life-threatening side effect.[A254242,L43942]

  2. Drug

    Lincomycin

    go.drugbank.com/drugs/DB01627
    ApprovedInvestigationalVet approved

    [A190657, A190621] Lincomycin was approved by the FDA on December 29, 1964.[L33214] … Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium _Streptomyces lincolnensis_ in Lincoln, Nebraska.

  3. Drug

    Trichloroacetate

    go.drugbank.com/drugs/DB11152
    ApprovedInvestigational

    In clinical chemistry and biochemistry, it is used as a precipitant of macromolecules including proteins, DNA and RNA. … Trichloroacetate, or trichloroacetic acid, is a strong acid prepared by the reaction of chlorine with acetic acid in the presence of a suitable catalyst.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.

  5. Drug

    Ribociclib

    go.drugbank.com/drugs/DB11730
    ApprovedInvestigational

    Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). … Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  6. Drug

    Somapacitan

    go.drugbank.com/drugs/DB15093
    ApprovedInvestigational

    [A219146] Somapacitan was granted FDA approval on 28 August 2020.[L15666] … Somapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency.

  7. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    Zanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2). … [A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]

  8. Drug

    Oditrasertib

    go.drugbank.com/drugs/DB21526
    Investigational

    Oditrasertib has a monoisotopic molecular weight of 295.11 Da. … Oditrasertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Oditrasertib is a serine/threonine kinase inhibitor.

  9. Drug

    Ruserontinib

    go.drugbank.com/drugs/DB21555
    Investigational

    Ruserontinib has a monoisotopic molecular weight of 443.25 Da. … Ruserontinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Ruserontinib is a tyrosine kinase inhibitor.

  10. Drug

    Vociprotafib

    go.drugbank.com/drugs/DB21559
    Investigational

    Vociprotafib has a monoisotopic molecular weight of 450.16 Da. … Vociprotafib is a small molecule drug. The usage of the INN stem '-protafib' in the name indicates that Vociprotafib is a human protein tyrosine phosphatase (HPTP) inhibitor.